Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. increased its position in Vir Biotechnology, Inc. (NASDAQ:VIR) by 13.6% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,134,276 shares of the company’s stock after purchasing an additional 136,087 shares during the period. Charles Schwab Investment Management Inc. owned 0.82% of Vir Biotechnology worth $8,496,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of VIR. Louisiana State Employees Retirement System grew its stake in Vir Biotechnology by 2.8% in the second quarter. Louisiana State Employees Retirement System now owns 43,800 shares of the company’s stock worth $390,000 after purchasing an additional 1,200 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Vir Biotechnology by 0.8% in the second quarter. Bank of New York Mellon Corp now owns 813,288 shares of the company’s stock valued at $7,238,000 after acquiring an additional 6,359 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Vir Biotechnology by 15.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 24,647 shares of the company’s stock valued at $219,000 after acquiring an additional 3,215 shares during the period. Innealta Capital LLC acquired a new position in Vir Biotechnology in the second quarter valued at approximately $32,000. Finally, Rhumbline Advisers boosted its stake in Vir Biotechnology by 4.3% in the second quarter. Rhumbline Advisers now owns 238,504 shares of the company’s stock valued at $2,123,000 after acquiring an additional 9,817 shares during the period. 65.32% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have commented on VIR shares. Needham & Company LLC restated a “buy” rating and issued a $19.00 target price on shares of Vir Biotechnology in a research note on Wednesday, November 20th. Barclays decreased their target price on Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. Finally, HC Wainwright restated a “buy” rating and issued a $110.00 target price on shares of Vir Biotechnology in a research note on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $36.40.

Vir Biotechnology Trading Down 7.2 %

VIR opened at $8.09 on Wednesday. The business’s 50 day moving average is $8.02 and its 200-day moving average is $8.71. The stock has a market cap of $1.11 billion, a PE ratio of -2.22 and a beta of 0.49. Vir Biotechnology, Inc. has a twelve month low of $6.56 and a twelve month high of $13.09.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings results on Thursday, October 31st. The company reported ($1.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.51). The business had revenue of $2.38 million for the quarter, compared to the consensus estimate of $5.54 million. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The business’s quarterly revenue was down 9.8% on a year-over-year basis. During the same period last year, the firm posted ($1.22) EPS. As a group, analysts forecast that Vir Biotechnology, Inc. will post -3.36 EPS for the current year.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).